Cutaneous Neurofibromatosis Type 1 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Neurofibromatosis 1 (NF1) is a genetic disorder characterized by the development of multiple noncancerous tumors of nerves and skin and areas of abnormal skin color. Areas of abnormal skin pigmentation typically include pale tan or light brown discolorations and freckling in atypical locations such as under the arms or in the groin. Penetrance approaches 100% by age 20; if the patient has the mutation, they will exhibit manifestations, although expressivity is highly variable, even among family members with the same mutation.
·
It affects males and females both in equal
numbers. NF1 affects all races and ethnic groups equally and is estimated to
occur in 1 in 2,500 to 3,000 births.
·
The disorder is inherited from a parent in
about 50% of individuals with NF1. Only one parent need to be affected to cause
a child to have NF1.
Thelansis’s “Cutaneous
Neurofibromatosis Type 1 Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Cutaneous
Neurofibromatosis Type 1 treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Cutaneous Neurofibromatosis Type 1 across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Cutaneous Neurofibromatosis Type 1 Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment